Executive officer

Michael Knell

Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer·Charles River Laboratories International, Inc.

About

M

i

c

h

a

e

l

G

.

K

n

e

l

l

i

s

I

n

t

e

r

i

m

C

h

i

e

f

F

i

n

a

n

c

i

a

l

O

f

f

i

c

e

r

,

C

o

r

p

o

r

a

t

e

S

e

n

i

o

r

V

i

c

e

P

r

e

s

i

d

e

n

t

,

a

n

d

C

h

i

e

f

A

c

c

o

u

n

t

i

n

g

O

f

f

i

c

e

r

o

f

C

h

a

r

l

e

s

R

i

v

e

r

L

a

b

o

r

a

t

o

r

i

e

s

.

H

e

j

o

i

n

e

d

t

h

e

C

o

m

p

a

n

y

i

n

A

p

r

i

l

2

0

1

7

a

s

C

o

r

p

o

r

a

t

e

S

e

n

i

o

r

V

i

c

e

P

r

e

s

i

d

e

n

t

a

n

d

C

h

i

e

f

A

c

c

o

u

n

t

i

n

g

O

f

f

i

c

e

r

.

I

n

t

h

i

s

r

o

l

e

,

M

r

.

K

n

e

l

l

i

s

r

e

s

p

o

n

s

i

b

l

e

f

o

r

p

r

o

v

i

d

i

n

g

s

t

r

a

t

e

g

i

c

g

u

i

d

a

n

c

e

t

o

t

h

e

f

i

n

a

n

c

e

g

r

o

u

p

s

,

i

n

c

l

u

d

i

n

g

d

i

r

e

c

t

i

o

n

o

f

t

h

e

G

l

o

b

a

l

A

c

c

o

u

n

t

i

n

g

,

F

i

n

a

n

c

i

a

l

P

l

a

n

n

i

n

g

a

n

d

A

n

a

l

y

s

i

s

,

a

n

d

T

a

x

f

u

n

c

t

i

o

n

s

;

m

a

i

n

t

a

i

n

i

n

g

t

h

e

C

o

m

p

a

n

y

'

s

f

i

s

c

a

l

r

e

c

o

r

d

s

;

a

n

d

p

r

e

p

a

r

i

n

g

i

t

s

f

i

n

a

n

c

i

a

l

r

e

p

o

r

t

s

.

H

e

a

l

s

o

o

v

e

r

s

e

e

s

t

h

e

d

e

s

i

g

n

a

n

d

o

p

e

r

a

t

i

o

n

o

f

t

h

e

C

o

m

p

a

n

y

'

s

s

y

s

t

e

m

o

f

i

n

t

e

r

n

a

l

c

o

n

t

r

o

l

s

,

e

n

s

u

r

i

n

g

c

o

m

p

l

i

a

n

c

e

w

i

t

h

t

h

e

r

u

l

e

s

a

n

d

r

e

g

u

l

a

t

i

o

n

s

o

f

t

h

e

S

a

r

b

a

n

e

s

-

O

x

l

e

y

A

c

t

.

I

n

O

c

t

o

b

e

r

2

0

2

5

,

M

r

.

K

n

e

l

l

w

a

s

a

p

p

o

i

n

t

e

d

b

y

t

h

e

B

o

a

r

d

t

o

a

c

t

a

s

t

h

e

C

o

m

p

a

n

y

'

s

i

n

t

e

r

i

m

C

h

i

e

f

F

i

n

a

n

c

i

a

l

O

f

f

i

c

e

r

,

e

f

f

e

c

t

i

v

e

u

p

o

n

t

h

e

S

e

p

t

e

m

b

e

r

2

0

2

5

d

e

p

a

r

t

u

r

e

o

f

F

l

a

v

i

a

H

.

P

e

a

s

e

,

s

e

r

v

i

n

g

a

s

t

h

e

C

o

m

p

a

n

y

'

s

p

r

i

n

c

i

p

a

l

f

i

n

a

n

c

i

a

l

o

f

f

i

c

e

r

u

n

t

i

l

a

p

e

r

m

a

n

e

n

t

s

u

c

c

e

s

s

o

r

i

s

n

a

m

e

d

.

T

h

e

C

o

m

p

a

n

y

s

u

b

s

e

q

u

e

n

t

l

y

a

n

n

o

u

n

c

e

d

t

h

e

a

p

p

o

i

n

t

m

e

n

t

o

f

G

l

e

n

n

C

o

l

e

m

a

n

a

s

C

o

r

p

o

r

a

t

e

E

x

e

c

u

t

i

v

e

V

i

c

e

P

r

e

s

i

d

e

n

t

a

n

d

C

h

i

e

f

F

i

n

a

n

c

i

a

l

O

f

f

i

c

e

r

(

w

i

t

h

a

t

e

n

t

a

t

i

v

e

s

t

a

r

t

d

a

t

e

o

f

A

p

r

i

l

6

,

2

0

2

6

)

,

a

f

t

e

r

w

h

i

c

h

M

r

.

K

n

e

l

l

c

o

n

t

i

n

u

e

s

i

n

h

i

s

r

o

l

e

a

s

C

o

r

p

o

r

a

t

e

S

e

n

i

o

r

V

i

c

e

P

r

e

s

i

d

e

n

t

a

n

d

C

h

i

e

f

A

c

c

o

u

n

t

i

n

g

O

f

f

i

c

e

r

.

P

r

i

o

r

t

o

j

o

i

n

i

n

g

t

h

e

C

o

m

p

a

n

y

,

M

r

.

K

n

e

l

l

s

e

r

v

e

d

a

s

t

h

e

C

h

i

e

f

A

c

c

o

u

n

t

i

n

g

O

f

f

i

c

e

r

a

n

d

V

i

c

e

P

r

e

s

i

d

e

n

t

o

f

F

i

n

a

n

c

e

a

t

B

r

u

k

e

r

C

o

r

p

o

r

a

t

i

o

n

f

r

o

m

2

0

1

2

t

o

2

0

1

7

.

H

e

w

a

s

w

i

t

h

E

r

n

s

t

&

Y

o

u

n

g

L

L

P

i

n

i

t

s

B

o

s

t

o

n

o

f

f

i

c

e

f

r

o

m

1

9

9

8

u

n

t

i

l

2

0

1

1

,

w

h

e

r

e

h

e

s

e

r

v

e

d

i

n

v

a

r

i

o

u

s

r

o

l

e

s

i

n

c

l

u

d

i

n

g

P

a

r

t

n

e

r

-

A

s

s

u

r

a

n

c

e

S

e

r

v

i

c

e

s

.

M

r

.

K

n

e

l

l

i

s

a

C

e

r

t

i

f

i

e

d

P

u

b

l

i

c

A

c

c

o

u

n

t

a

n

t

i

n

M

a

s

s

a

c

h

u

s

e

t

t

s

a

n

d

h

o

l

d

s

a

B

.

S

.

d

e

g

r

e

e

i

n

B

u

s

i

n

e

s

s

A

d

m

i

n

i

s

t

r

a

t

i

o

n

f

r

o

m

t

h

e

S

t

a

t

e

U

n

i

v

e

r

s

i

t

y

o

f

N

e

w

Y

o

r

k

a

t

B

u

f

f

a

l

o

.

Since April 2017
Age 49
Tenure 9 yrs

Also at Charles River Laboratories International, Inc.

JF James C. Foster Chair, President and Chief Executive Officer BG Birgit Girshick Corporate Executive Vice President and Chief Operating Officer (Chief Executive Officer effective May 5, 2026) NA Nancy C. Andrews Director (Executive Vice President and Chief Scientific Officer, Boston Children's Hospital) SB Steven Barg Director (Global Co-Head of Engagement, Elliott Investment Management L.P.) AC Abraham Ceesay Director (Chief Executive Officer, Rapport Therapeutics) ME Mark Enyedy Director (Former President and Chief Executive Officer, ImmunoGen, Inc.)

Roles

Organization Role Dates Details
Charles River Laboratories International, Inc. Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer April 2017–present Current role
Charles River Laboratories International, Inc. Corporate Senior Vice President and Chief Accounting Officer Apr 2017 Appointed interim Chief Financial Officer in October 2025 upon the departure of Flavia H. Pease.
Bruker Corporation Chief Accounting Officer and Vice President of Finance 2012 - 2017
Ernst & Young LLP Various roles including Partner - Assurance Services 1998 - 2011 Based in the Boston office.
Ernst & Young LLP Partner, Assurance Services 1998-2011

Related

Company Charles River Laboratories International, Inc. Company hub Person James C. Foster Chair, President and Chief Executive Officer Person Birgit Girshick Corporate Executive Vice President and Chief Operating Officer (Chief Executive Officer effective May 5, 2026) Person Nancy C. Andrews Director (Executive Vice President and Chief Scientific Officer, Boston Children's Hospital) Person Steven Barg Director (Global Co-Head of Engagement, Elliott Investment Management L.P.) Person Abraham Ceesay Director (Chief Executive Officer, Rapport Therapeutics) Person Mark Enyedy Director (Former President and Chief Executive Officer, ImmunoGen, Inc.) Person Paul Graves Director (Former Chief Executive Officer, Rio Tinto Lithium) Person Reshema Kemps-Polanco Director (Executive Vice President and Chief Commercial Officer, Novartis US) Person George Llado, Sr. Director (Former Senior Vice President and Chief Information Officer, Alexion Pharmaceuticals, Inc.) Person Martin W. Mackay Director (Lead Independent Director; Co-Founder and Non-Executive Chair, Rallybio Corporation) Person Craig B. Thompson Director (President Emeritus and Former President and Chief Executive Officer, Memorial Sloan Kettering Cancer Center) Person Virginia M. Wilson Director (Retired Senior Executive Vice President and Chief Financial Officer, TIAA) Deal Charles River Laboratories International Agilux Laboratories 2016 Deal page Deal Charles River Laboratories International Argenta And Biofocus Cro Services Division Of Galapagos 2014 Deal page Deal Charles River Laboratories International Blue Stream Laboratories 2016 Deal page
Source: Charles River Laboratories International, Inc. SEC filings and official company website

See how VectorShift works for your firm

Request Demo